The study shows that noscapine
inhibited tumor growth in mice and also limited the spread of tumors without causing any side effects.
has previously been studied as a treatment for breast, ovarian, colon, lung and brain cancer and for various lymphomas, chronic lymphocytic leukemia and melanoma.
17 Proceedings of the National Academy of Sciences, believe that noscapine
exerts its anticancer effects by binding tubulin, a protein that forms the cellular filaments called microtubules.
The unexpected anti-fibrotic activity observed with Noscapine
in animals encourages us to consider moving forward with clinical trials to more fully assess its potential.
com adds "Global and Chinese Noscapine
(CAS 128-62-1) Industry, 2009-2019 Market Research Report" to its store.
We also look to continue to advance our second clinical stage drug candidate CB3304, noscapine
, in its Phase I/II trial in multiple myeloma during the second half of 2008," added Mr.
Assessment by Mechanism of Action 60 Assessment by Route of Administration 64 Assessment by Molecule Type 66 Drug Profiles 69 fresolimumab - Drug Profile 69 PF-06473871 - Drug Profile 71 BTT-1023 - Drug Profile 72 SDP-051 - Drug Profile 74 Lpathomab - Drug Profile 75 disitertide - Drug Profile 76 ixmyelocel-T - Drug Profile 78 AZX-100 - Drug Profile 81 noscapine
- Drug Profile 84 INT-767 - Drug Profile 85 GED-0507 - Drug Profile 87 MGN-4220 - Drug Profile 88 PBI-4050 - Drug Profile 89 PBI-4419 - Drug Profile 90 Tankyrase/Wnt Inhibitors - Drug Profile 91 NMIL-121 - Drug Profile 92 GC-4403 - Drug Profile 93 RP6503 - Drug Profile 94 HL-156Fib - Drug Profile 95 Project MITRA - Drug Profile 96 FT-071 - Drug Profile 97 FT-061 - Drug Profile 98 FT-026 - Drug Profile 99
(Cougar Biotechnology), an Orally Active Alkaloid Showing Early Promise
Cougar Biotechnology's oncology portfolio includes abiraterone acetate (CB7630), an orally available targeted inhibitor of the steroidal enzyme known as 17-alpha hydroxylase/C17,20 lyase, which is currently being studied in two Phase III clinical trials in prostate cancer and a Phase I/II trial in breast cancer; noscapine
(CB3304), an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and seocalcitol (CB1089), an analog of vitamin D, which has been clinically tested in a number of solid tumor types.
15 /PRNewswire-USNewswire/ -- A presentation made at the 17th International Prostate Cancer Update Conference in Vail, Colorado, has shown noscapine
to be effective against prostate cancer.
The preclinical studies demonstrate that noscapine
exhibits potent antitumor activity against non-Hodgkin's lymphoma and myeloma in vitro as well as in vivo in xenograft models.
At each dose level, noscapine
was administered orally on a three times a day schedule for 49 days.